![]() |
市場調查報告書
商品編碼
1433455
全球迴旋加速器市場 2023-2030Global Cyclotron Market 2023-2030 |
在預測期內(2023-2030年),全球迴旋加速器市場預計將以11.2%的CAGR成長。市場成長歸因於癌症患病率不斷上升和診斷成像程序的使用不斷增加等因素。根據世界衛生組織的資料,癌症是全球主要死亡原因,2020年將導致近 1,000 萬人死亡,即近六分之一的死亡。2020年新增癌症病例包括乳癌(226萬例)、肺癌(221萬例)、結腸癌和直腸癌(193萬例)。多種生活方式因素會導致癌症的發生,例如加工肉類攝取量高、水果和蔬菜攝取量低、久坐的生活方式、肥胖、吸煙和過量飲酒。
全球迴旋加速器市場依產品和應用進行細分。根據產品,市場細分為迴旋加速器10-12MeV、迴旋加速器16-18MeV、迴旋加速器19-24MeV和24MeV以上迴旋加速器。此外,根據應用,市場細分為醫療和工業。在這些產品中,迴旋加速器10-12 MeV 細分市場預計將佔據相當大的市場佔有率,因為迴旋加速器10-12 MeV 系列有助於生產用於醫學成像的放射性同位素,特別是在正子斷層掃描中(PET)。
在這些應用中,醫療細分市場預計將在全球迴旋加速器市場中佔據相當大的佔有率。此細分市場的成長歸因於各種醫學影像技術(例如正子斷層掃描(PET))在放射性藥物生產中的使用不斷增加,以及對準確疾病診斷的核子醫學程序的需求不斷增加。核子醫學程序對於檢測和監測各種醫療狀況非常重要。根據世界核能協會統計,全球每年約有4,000萬例核醫手術,年增率為5.0%。全球有超過 10,000 家醫院在醫學中使用放射性同位素,約 90%的手術用於診斷。診斷中最常使用的放射性同位素是锝-99(Tc-99m),約佔全球所有核子醫學程序的 80%和核子醫學診斷掃描的 85%。
全球迴旋加速器市場根據地理位置進一步細分,包括北美(美國和加拿大)、歐洲(英國、義大利、西班牙、德國、法國和歐洲其他地區)、亞太地區(印度、中國、日本、韓國、亞洲其他地區)以及世界其他地區(中東和非洲以及拉丁美洲)。其中,預計亞太地區在預測期內的CAGR最高。醫療技術不斷進步,可支配收入不斷增加以及新興經濟體醫療基礎設施的改善推動亞太地區的迴旋加速器市場。
癌症發病率的上升,政府的有利舉措以及高度發展的醫療基礎設施是推動該地區市場的關鍵因素。根據美國癌症協會的《2022年癌症事實與資料》,預計2022年美國將新增約 1,918,030 例癌症病例,並有 609,360 人因癌症死亡。該地區如此高的癌症發病率預計將增加癌症的採用率迴旋加速器用於癌症診斷,推動了該地區的市場成長。
服務於迴旋加速器市場的主要公司包括Siemens Medical Solutions USA, Inc.、IBA Radiopharma Solutions、GE HealthCare、Advanced Cyclotron Systems, Inc.等。市場參與者透過各種策略(包括併購、合作、合作、融資和新產品發布),為市場成長做出了巨大貢獻,以保持市場競爭力。例如,2023年1月,Fusion Pharmaceuticals Inc.和BWX Technologies, Inc.的子公司BWXT Medical Ltd.簽訂了供應actinium-225的優先合作夥伴協議。根據協議,BWXT Medical 按批量定價提供 Fusion 預定數量的錒供應需求。
Global Cyclotron Market Size, Share & Trends Analysis Report by Product (Cyclotron 10-12MeV, Cyclotron 16-18MeV, Cyclotron 19-24MeV, and Cyclotron above 24MeV), by Application(Medical, and Industrial), Forecast Period (2024-2031)
The global cyclotron market is anticipated to grow at a CAGR of 11.2% during the forecast period (2023-2030).The market growth is attributed to factors such as the growing prevalence of cancer and the increasing use of diagnostic imaging procedures. According to the World Health Organization, cancer is a leading cause of death around the globe, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. In terms of new cases of cancer in 2020 included breast (2.26 million cases);lung (2.21 million cases);colon and rectum (1.93 million cases). Several lifestyle factors contribute to the development of cancer such as a high intake of processed meats and low intake of fruits and vegetables, a sedentary lifestyle, obesity, smoking, and excessive alcohol consumption.
The global cyclotron market is segmented on the product and application. Based on the product, the market is sub-segmented into cyclotron 10-12MeV, cyclotrons 16-18MeV, cyclotron 19-24MeV, and cyclotron above 24MeV.Further, based on application, the market is sub-segmented into medical, and industrial. Among the products, the cyclotron 10-12 MeV sub-segment is anticipated to hold a considerable share of the market, owing to the cyclotron 10-12 MeV range being instrumental in the production of radioisotopes used for medical imaging, particularly in positron emission tomography (PET).
Among the applications, the medical sub-segment is expected to hold a considerable share of the global cyclotron market. The segmental growth is attributed to the increasing use in radiopharmaceutical production in various medical imaging techniques, such as positron emission tomography (PET), and increasing demand in nuclear medicine procedures for accurate disease diagnosis. Nuclear medicine procedures are vital for detecting and monitoring various medical conditions. According to the World Nuclear Association, about 40 million procedures are carried out each year globally with nuclear medicines, with an annual growth rate of 5.0% per annum. Over 10,000 hospitals globally use radioisotopes in medicine, and about 90% of the procedures are for diagnosis. The most common radioisotope used in diagnosis is technetium-99 (Tc-99m), accounting for about 80% of all nuclear medicine procedures and 85% of diagnostic scans in nuclear medicine around the globe.
The global cyclotron market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, Asia Pacific is anticipated to exhibit highest CAGR during the forecast period. The advancing medical technologies, rising disposable income, and improving healthcare infrastructure in emerging economies are driving the cyclotron market in the Asia-Pacific.
The rising prevalence of cancer, favorable government initiatives, and highly developed healthcare infrastructure is a key factor driving the regional market. According to the American Cancer Society 'Cancer Facts & Figures 2022', around 1,918,030 new cancer cases and 609,360 mortalities due to cancers are estimated in the US in the year 2022. Such a high incidence of cancers in this region is anticipated to increase the adoption of cyclotrons for the diagnosis of cancer, driving market growth in this region.
The major companies serving the cyclotron market include Siemens Medical Solutions USA, Inc., IBA Radiopharma Solutions, GE HealthCare, Advanced Cyclotron Systems, Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in January 2023, Fusion Pharmaceuticals Inc., and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. entered into a preferred partner agreement for the supply of actinium-225. Under the agreement, BWXT Medical offered predetermined amounts of Fusion's actinium supply needs at volume-based pricing.